Ocular Drug Delivery: Advancements and Innovations
Open accessThe DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.
Abstract
Ocular drug delivery has been significantly advanced for not only pharmaceutical compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so forth, but also for the rapidly progressed gene therapy products. For conventional non-gene therapy drugs, appropriate surgical approaches and releasing systems are the main deliberation to achieve adequate treatment outcomes, whereas the scope of “drug delivery” for gene therapy drugs further expands to transgene construct optimization, vector selection, and vector engineering. The eye is the particularly well-suited organ as the gene therapy target, owing to multiple advantages. In this review, we will delve into three main aspects of ocular drug delivery for both conventional drugs and adeno-associated virus (AAV)-based gene therapy products: (1) the development of AAV vector systems for ocular gene therapy, (2) the innovative carriers of medication, and (3) administration routes progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Presently, there are more than 40 active clinical trials or follow ups for ocular diseases using AAV vectors alone.154”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 9×
“Since the advent of the first FDA‐approved gene therapy, LuxturnaTM, for the treatment of type 2 Leber congenital amaurosis (LCA) [4], ophthalmic gene therapy research has blossomed.”
BackgroundMethodInfluentialDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“They are small (~26 nm diameter), icosahedral-structured capsid, non-enveloped, singlestranded DNA, non-pathogenic viruses [11].”
BackgroundNanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,226
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Research works printed but not linked: 10
- Komaromy, A.M.; Harman, C.; Koehl, K.; Anderson, A.; Boye, S.L.; Steibel, J.P.; Teixeira, L.; Toris, C.B.; Moroi, S.E.; Boye, S.E. Four-year follow up of intraocular pressure (IOP) control in a canine model of open-angle glaucoma (OAG) treated with adeno-associated virus (AAV)-mediated modification of gene expression within the aqueous humor outflow pathways (AHOP). Investig. Ophthalmol. Vis. Sci. 2021, 62, 2783.
- Visuvanathan, S. The Effects of AAV-Mediated XIAP Gene Therapy in a Mouse Model of Glaucoma. Master's Thesis, Université d'Ottawa/University of Ottawa, Ottawa, ON, Canada, 2019.
- Bilsbury, E.; Su, W.; Sun, S.; Doherty, S.; Wood, E.; Ke, X.; Zheng, Q.; Tai, P.W.; Lin, H.; Gao, G. AAV-mediated anti-VEGF therapeutics increase corneal allograft survival-rate in a model of high-risk corneal transplantation. Investig. Ophthalmol. Vis. Sci. 2022, 63, 72-A0045.
- Garrigue, J.-S.; Lambert, G.; Rabinovich, L.; Daull, P.; Serle, J.B. A Comparative Study of Latanoprost-Cationic Emulsion (Catioprost) and Latanoprost Aqueous Solution (Xalatan) in Preclinical Efficacy and Safety Models. Investig. Ophthalmol. Vis. Sci. 2011, 52, 238.
- Biswas, G.R.; Majee, S.B. Niosomes in ocular drug delivery. Eur. J. Pharm. Med. Res 2017, 4, 813-819.
- Avti, P.; Patel, S.; Sitharaman, B. Nanobiomaterials Handbook; CRC Press: Boca Raton, FL, USA, 2016.
- Van Ooteghem, M.M. (2019). Biopharmaceutics of Ocular Drug Delivery, CRC Press.
- Varma, 2018, Sustained release drug delivery: Closer than you think, Glaucoma Today, 3, 58
- Sedlavek, 1965, Possibilities of application of ophthalmic drugs with the aid of gel contact lens, Cesk. Oftalmol., 21, 509
- Wang, 2015, Lipid Nanoparticles for Ocular Gene Delivery, J. Funct. Biomater., 6, 379, 10.3390/jfb6020379 · DOI · Paper page
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Mucoadhesive-to-Mucopenetrating Nanoparticles for Mucosal Drug Delivery: A Mini Review
Zheng, B., Liu, D., Qin, X., Zhang, D., & Zhang, P. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s505427 · Cited by 71
“As a result, insufficient release of the mucus-penetrating ligands eventually leads to the retention of nanoparticles in the mucus layer and their removal.”
How can machine learning and multiscale modeling benefit ocular drug development?
Wang, N., Zhang, Y., Wang, W., Ye, Z., Chen, H., Hu, G., & Ouyang, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114772 · Cited by 58
Kannan, R. M., Pitha, I., & Parikh, K. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115005 · Cited by 53
Chandel, A., & Kandav, G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105785 · Cited by 55
Current developments of gene therapy in human diseases
Liu, F., Li, R., Zhu, Z., Yang, Y., & Lu, F. (2024) · MedComm · doi:10.1002/mco2.645 · Cited by 48
Ferulic Acid: A Comprehensive Review
Purushothaman, J., & Rizwanullah, M. (2024) · Cureus · doi:10.7759/cureus.68063 · Cited by 83
“The advantages of ocular drug delivery include targeted therapy directly to the site of action, which enhances drug efficacy and reduces systemic side effects, and it provides a non-invasive, patient-friendly method of administration [99].”
BackgroundMitrović, D., Zaklan, D., Đanić, M., Stanimirov, B., Stankov, K., Al‐Salami, H., & Pavlović, N. (2025) · Molecules · doi:10.3390/molecules30051181 · Cited by 42
Three Major Causes of Metabolic Retinal Degenerations and Three Ways to Avoid Them
Kovács-Valasek, A., Rák, T., Pöstyéni, E., Csutak, A., & Gabriel, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108728 · Cited by 37
“A higher prevalence of depression was also found in AMD patients, and schizophrenic patients have significantly reduced retinal thickness and retinal blood flow [24,26].”
BackgroundLiu, X., Huang, K., Zhang, F., Huang, G., Wang, L., Wu, G., Ren, H., Yang, G., & Lin, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02614-1 · Cited by 30
“These models are therefore essential for characterizing the physical and chemical properties of intelligent NIM delivery Systems including particle size, morphology, stability, sterility, permeability, the efficiency of drug release, and in vitro cellular biocompatibility and toxicity [103].”
BackgroundAdeno-associated virus therapies: Pioneering solutions for human genetic diseases
Liu, D., Tian, L., Liu, L., Che, X., Li, X., Liu, C., & Wu, G. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.09.003 · Cited by 32
Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis
Teabagy, S., Wood, E., Bilsbury, E., Doherty, S., Janardhana, P., & Lee, D. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114869 · Cited by 29
Self-citationAdeno-associated virus vectors for retinal gene therapy in basic research and clinical studies
Xia, X., & Guo, X. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1310050 · Cited by 25
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1148795 · Cited by 21
Functional Peptide-Loaded Gelatin Nanoparticles as Eyedrops for Cornea Neovascularization Treatment
Chu, Y.-C., Fang, H., Wu, Y., Tang, Y.-J., Hsieh, E.-H., She, Y., Chang, C.-Y., Lin, I., Chen, Y., Liu, G., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s398769 · Cited by 21
Seeing the Future: A Review of Ocular Therapy
Whalen, M., Akula, M., McNamee, S. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11020179 · Cited by 21
“The nanoparticles that are currently being tested for ocular therapeutic delivery include nanomicelles, liposomes, dendrimers, and peptides, which greatly increase the ocular residence time for therapeutics while also allowing for sustained release of therapeutics [11,225].”
BackgroundTorkashvand, A., Izadian, A., & Hajrasouliha, A. R. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.07.002 · Cited by 19
Brock, D. C., Wang, M., Hussain, H. M. J., Rauch, D. E., Marra, M. H., Pennesi, M. E., Yang, P. G., Everett, L. A., Ajlan, R., Colbert, J., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae028 · Cited by 14
Ansari, M., Gupta, C., Kulkarni, Y. A., & Singh, K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125235 · Cited by 10
Advances of nanoparticles in transmucosal drug delivery
Zhang, L., Yang, C., Song, Y., Sheng, T., Li, J., Yu, J., Wu, X., & Ye, X. (2023) · Nano Research · doi:10.1007/s12274-023-6188-7 · Cited by 9
Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug
Shree, D., Patra, C. N., & Sahoo, B. M. (2023) · Pharmaceutical Nanotechnology · doi:10.2174/2211738511666230816090046 · Cited by 8
Casey-Power, S., Vardar, C., Ryan, R., Behl, G., McLoughlin, P., Byrne, M. E., & Fitzhenry, L. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.10.004 · Cited by 6
Li, J., Gao, Z., Ning, L., Yao, L., Liu, C., Xu, C., Ren, X., Wang, A., Gao, S., Wang, M., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s464524 · Cited by 5
Barbalho, G. N., Falcão, M. A., Amaral, V. A., Contarato, J. L. A., Gelfuso, G. M., Filho, M. C., & Gratieri, T. (2024) · Methods · doi:10.1016/j.ymeth.2024.07.010 · Cited by 5
Breaking the ocular barrier through nano-lipid carriers to treat intraocular diseases
Giri, S., Badwaik, H. R., & Giri, T. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104867 · Cited by 5
Muñoz-Villaescusa, C., van der Ven, D. L., Quetzeri-Santiago, M. A., & Rivas, D. F. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115792 · Cited by 6
Advancements in Ocular Modelling and Simulations: Key Considerations and Case Studies
Khan, M. S., Murthy, A. N., & Ahmed, T. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-03001-7 · Cited by 4
“The inner limiting membrane seals the vitreous humour, a gel-filled sac that extends to the macula behind the lens in the posterior segment [10–12].”
Wang, B., Zhang, M., Chen, W., Yin, C., Zhao, H., Chen, G., & Cao, F. (2025) · Biomaterials Science · doi:10.1039/d5bm00453e · Cited by 4
Quan, Z., Liu, X., Lü, Y., Pan, J., Liu, C., Pan, W., Li, Y., Huang, Y., & Sun, J. M. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110694 · Cited by 4
Extracellular Vesicles in Ophthalmology: From Natural Nanocarriers to Engineered Therapeutics
Flores, C., Mastantuono, F., Huang, L. J., McKay, T. B., Coyne, G., Hefley, B. S., Vasini, B., Karamichos, D., & Yang, M. (2026) · Bioengineering · doi:10.3390/bioengineering13030275 · Cited by 3
“Notable examples include the blood–retina barrier, the tight junctions between retinal pigment epithelial cells, and the tight junctions of the corneal epithelium [10].”
Chemically modified hyaluronic acid derivatives as ocular drug carriers: A review
Sen, O., De, S., Dey, G., Das, S., Bhowmik, M., Jana, S., Nandi, G., & Manna, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145049 · Cited by 5
Foster, T., Lim, P., Ionescu, C. M., Wagle, S. R., Kovačević, B., Mooranian, A., & Al‐Salami, H. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106070 · Cited by 3
Recent Advancement in Ocular Drug Delivery System: A Systematic Review
Mittal, C., Amle, V. S., Kumar, R., Sood, P., Uniyal, A., & Singh, H. (2023) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.2.3.32 · Cited by 5
Jani, H., Ranch, K. M., Lalwani, R., Patel, Y., Bodiwala, K. B., & Gajjar, A. K. (2024) · Current Pharmaceutical Analysis · doi:10.2174/0115734129341673241106101546 · Cited by 2
Manufacturing consideration, scale-up, and validation in sterile ophthalmic formulation
Üner, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33781-9.00020-4 · Cited by 2
Ophthalmology: Navigating ocular barriers with advanced nanocarriers
Mustafa, S. (2024) · German Journal of Pharmaceuticals and Biomaterials · doi:10.5530/gjpb.2024.3.10 · Cited by 2
Advances in the application of gelatin-based materials in anterior segment diseases
Zhang, Z., An, C., Yan, C., Jin, L., Dong, H., Qi, Y., Wang, H., & Zhang, L. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142695 · Cited by 2
Ocular drug delivery in the era of nanomedicine, gene therapy, and digital twins
Choudhary, K., Kumar, A., Kumar, M., Patel, P., & Kurmi, B. D. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108318 · Cited by 1
Ganvenwaer, R., Pradhan, S., Jadhav, K., Vinchurkar, K., & Doke, R. R. (2026) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2026.1927008 · Cited by 1
Ocular Gene Therapy: Literature Review
Naser, M., Nasr, M., & Shehata, L. H. (2023) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v40.2.5623 · Cited by 1
Translating discoveries as novel biomarkers and interventions in ophthalmology
Broadhead, G., & Khachigian, L. M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04216-1
“Utilization of novel therapeutics in this setting requires an understanding of specific intraocular pharmacokinetics and pharmacodynamics, and that of delivery modalities and their properties [2].”
BackgroundActualización en Oftalmología Tomo 10
Quijije, K. A. S., Arrobo, E. C. R., Verdezoto, D. A. Y., de Aparicio, C. X. P., & Puente, G. A. M. (2024) · doi:10.56470/978-9942-680-82-2
Biocompatible Ocular Films: A Novel Approach to Prolonged Aceclofenac Release and Mucoadhesion
Dwivedi, J., Aziz, N., Wal, P., Bhattacharjee, A., Imran, M., & Nainwal, P. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10130-4
“Structures such as the cornea, blood-aqueous barrier, and rapid clearance mechanisms, such as blinking and tear production, limit drug absorption and retention [4].”
Advanced packaging, containers, and closure systems for complex ophthalmic products
Maurya, R., Vikal, A., Patel, P., Singh, N. K., Singh, C., & Kurmi, B. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33781-9.00008-3 · Cited by 1
Fixed-dose combination techniques in ophthalmic products
Ansari, M. D., Majid, H., Aqil, M., & Sultana, Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33781-9.00012-5
Uveitis Management at the Crossroads of Pharmacotherapy, Nanotechnology, and Intellectual Property
Pandey, A., Bhawale, R., Vasave, R., Khan, O., Chigurupati, S. P. D., Kumari, N. U., Luthra, K., & Mehra, N. K. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.6c00351
Random Copolyester-Based Delivery Systems for Tear Protein Therapeutics in Ocular Surface Disorders
Astolfi, G., Guidotti, G., Soccio, M., Dominici, F., Puglia, D., Lotti, N., Ponzini, E., Tavazzi, S., Versura, P., & Fontana, L. (2026) · ACS Omega · doi:10.1021/acsomega.5c09194
Advances in nanomedicine for ocular inflammatory diseases
Xiang, D., Feng, X., & Zhang, J. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.102965 · Cited by 1
Polymer used in 3D printed ocular drug delivery system
Mali, C., & Bagade, S. B. (2026) · International Journal of Polymeric Materials · doi:10.1080/00914037.2026.2682860
Feng, Y., & Zhang, M. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.174 · Cited by 1
Lungu, I. I., Stafie, L., Ştefanache, A., Stefan, D.-C., Lungu, A., Sarbu, G.-E., Savin, L., Guraliuc, A., Dohotariu, F. C., & Anton, N. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091181
“Second, terminal sterilization poses formidable challenges, as all ophthalmic preparations must ensure absolute sterility without compromising carrier stability [10,40].”
Karale, P., Pagar, D., Ware, A., Gosavi, S., Narang, A., Sutar, N., Chaudhari, N. B., Borse, S., Pholane, A., & Shendge, R. S. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.87s.10
Metadata
- Authors
- Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Gao, Guangping
- Lin, Haijiang
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-09-13
- Volume
- 14
- Issue
- 9
- Pages
- 1931
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9506479
- OpenAlex
- W4296005586
- Cited by
- 50
- References
- 134
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 14 · 2023: 15
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- BrightFocus Foundation (M2019074)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- ocular drug delivery, ocular gene therapy, adeno-associated virus vectors, vector selection, gene therapy vectors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.